1. Maris PJG Jr, Mandal AK, Netland PA. Medical therapy of pediatric glaucoma and glaucoma in pregnancy. Ophthalmol Clin North Am. 2005;18:461-468.

2. Chung CY, Kwok AK, Chung KL. Use of ophthalmic medications during pregnancy. Hong Kong Med J. 2004;10:191-195.

3. Becker B, Friedenwald JS. Clinical aqueous outflow. AMA Arch Ophthalmol. 1953; 50:557-571.

4. Kass MA, Sears ML. Hormonal regulation of intraocular pressure. Surv Ophthalmol. 1977;22:153-176.

5. Sunness JS. The pregnant woman's eye. Surv Ophthalmol. 1988;32:219-238.

Brauner SC, Chen TC, Hutchinson BT, Chang MA, Pasquale LR, Grosskreutz CL. The course of glaucoma during pregnancy: a retrospective case series. Arch Ophthalmol. 2006;124:1089-1094.

Kooner KS, Zimmerman TJ. Antiglaucoma therapy during pregnancy—part II. Ann Ophthalmol. 1988;20:208-211.

Salamalekis E, Kassanos D, Hassiakos D, Chrelias C, Ghristodoulakos G. Intra/extra-amniotic administration of prostaglandin F2a in fetal death, missed and therapeutic abortions. Clin Exp Obstet Gynecol. 1990;17:17-21.

Andrade SE, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004; 191:398-407.

Lustgarten JS, Podos SM. Topical timolol and the nursing mother. Arch Ophthalmol. 1983;101:1381-1382.

Yang CB, et al. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol. 1998;126:600-602. Altuna JC, et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J. Glaucoma. 1999;8:199-203.

Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol. 2003;87:1091-1093.

Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S129-S132.

Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS. 1999;3:33-39.

Boger WP III, Walton DS. Timolol in uncontrolled childhood glaucomas. Ophthalmology. 1981;88:253-258.

McMahon CD, Hetherington J Jr, Hoskins HD Jr, Shaffer RN. Timolol and pediatric glaucomas. Ophthalmology. 1981;88:249-252.

Zimmerman TJ, Kooner KS, Morgan KS. Safety and efficacy of timolol in pediatric glaucoma. Surv Ophthalmol. 1983;28(suppl):262-264.

Hoskins HD Jr, Hetherington J Jr, Magee SD, Naykhin R, Migliazzo CV. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol. 1985;103:1163-1165. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.

Harte VJ, Timoney RF. Drug prescribing in paediatric medicine. Ir Med J. 1980;73: 157-161.

Burnstine RA, Felton JL, Ginther WH. Cardiorespiratory reaction to timolol maleate in a pediatric patient: a case report. Ann Ophthalmol. 1982;14:905-906. Bailey PL. Timolol and postoperative apnea in neonates and young infants. An-esthesiology. 1984;61:622.

Olson RJ, Bromberg BB, Zimmerman TJ. Apneic spells associated with timolol therapy in a neonate. Am J Ophthalmol. 1979;88:120-122.

Futagi Y, Otani K, Abe J. Growth suppression in children receiving acetazolamide with antiepileptic drugs. Pediatr Neurol. 1996;15:323-326.

Ritch R. Special Therapeutic Situations. In: Netland PA, Allen RC, eds. Glaucoma Medical Therapy: Principles and Management. San Francisco, CA: American Academy of Ophthalmology; 1999:193-201.

Haas J. Principles and problems of therapy in congenital glaucoma. Invest Ophthal-mol. 1968;7:140-146.

Shaffer RN. New concepts in infantile glaucoma. Trans Ophthalmol Soc U K. 1967; 87:581-590.

29. Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS. 1998;2:43-47.

30. Ott EZ, et al. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol. 2005;123:1177-1186.

31. Pollack IP, Quigley HA, Harbin TS. The Ocusert pilocarpine system: advantages and disadvantages. South Med J. 1976;69:1296-1298.

32. Jones DE, Watson DM. Angle-closure glaucoma precipitated by the use of phospho-line iodide for esotropia in a child. Br J Ophthalmol. 1967;51:783-785.

33. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5:281-284.

34. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye. 2004;18:24-26.

35. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila). 2004;43:99-101.

36. Berlin RJ, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138: 441-443.

37. Al-Shahwan S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112:2143.

0 0

Post a comment